Left ventricular hypertrophy and calcium, phosphate related factors in chronic hemodialysis patients

AUTHORS

HR Samimagham 1 , M Sahebjame 2 , a haghighi 3 , * , M Javidan 4

1 Dept of internal medicine, Faculty of Medicine, Hormozgan University of Medical Sciences and Health Services, Bandarabas, Iran.

2 Dept of Cardiology, Faculty of Medicine, Iran University of Medical Sciences and Health Services, Tehran, Iran.

3 Dept of Rheumatology, Faculty of Medicine, Iran University of Medical Sciences and Health Services Tehran, Iran.

4 Dept of internal medicine, Faculty of Medicine, Shahid Sadoghi University of Medical Sciences and Health Services, Yazd, Iran.

How to Cite: Samimagham H, Sahebjame M, haghighi A, Javidan M. Left ventricular hypertrophy and calcium, phosphate related factors in chronic hemodialysis patients, Zahedan J Res Med Sci. 2007 ; 9(4):e94759.

ARTICLE INFORMATION

Zahedan Journal of Research in Medical Sciences: 9 (4); e94759
Published Online: October 30, 2007
Article Type: Research Article
Received: September 30, 2006
Accepted: September 30, 2007
READ FULL TEXT

Abstract

Background: Left ventricular hypertrophy (LVH) is reported to be common in chronic
hemodialysis patients and also increases risk for mortality and morbidity in such patients. Effects of
PTH on LVH are approved by clinical and experimental studies. Therefore, PTH control is
important in LVH prevention. In some centers PTH can be measured, so we conducted a descriptive
study about the relationship between Ca, P, alkaline phosphatase and LVH in chronic hemodialysis
patients.
Materials and Methods: 56 chronic hemodialysis patients were included in this descriptiveanalytical
study and followed for one year. The patients were divided into LVH group and non-
LVH group by echocardiographic findings. The mean Ca, P, Alkaline Phosphatase (Alk),Ca×P
product, Hb, HCT ,serum Albumin were checked monthly moreover HTN frequency, hemodialysis
duration, cardiac calcification and ACE in, EPO use were compared in the two groups.
Relationship between these factors and LVH was evaluated using Chi-Square T.test and fisher-
Exact test.
Results: Results showed that 32 patients (57.1%) had LVH, among them 19 patients (59.4%)
were male and 13 patients were (40.6%) female (P<0.05). Mean age of patients with LVH was
53.5+13.3 which had not statistically significant difference with patients without LVH (P>0.05).
The mean serum levels of Ca, P, Alk P, Hb were not significantly different in both groups but mean
of Ca×P product was significantly higher in the LVH group(P<0.05) (58.7±16.6 versus
47.6±18.2).
Discussion: HTN control, ACE inhibitor and EPO use are important in prevention of LVH in
chronic hemodialysis patients but maintenance of Ca×P product in acceptable level is another
important factor for this prevention.

Fulltext

The full text of this article is available on the PDF file.

References

  • 1.

    The References of this article are available on the PDF file.

  • © 2007, Zahedan Journal of Research in Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
    COMMENTS

    LEAVE A COMMENT HERE: